3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Multiple Myeloma
4
Neoplasm, Residual
3
Neoplasm Metastasis
3
Carcinoma, Non-Small-Cell Lung
3
Colorectal Neoplasms
2
Pancreatic Neoplasms
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neoplasms
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Myeloid, Acute
1
Fallopian Tube Neoplasms
1
Burkitt Lymphoma
1
Interventions
Cyclophosphamide
116
fludarabine phosphate
101
Busulfan
83
Tacrolimus
75
fludarabine
73
Mycophenolic Acid
71
Whole-Body Irradiation
65
Peripheral Blood Stem Cell Transplantation
59
Antilymphocyte Serum
58
Cyclosporine
53
Azacitidine
53
Melphalan
50
Cytarabine
47
Filgrastim
43
Methotrexate
41
Granulocyte Colony-Stimulating Factor
34
Decitabine
33
Radiotherapy
28
Thiotepa
27
Cord Blood Stem Cell Transplantation
27
thymoglobulin
26
Stem Cell Transplantation
26
Clofarabine
22
Methylprednisolone
20
Sirolimus
19
Alemtuzumab
16
venetoclax
15
Specimen Handling
14
sargramostim
13
Etoposide
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Myelodysplastic Syndromes
×
Maintenance
×
Clear all
NCT07572929
2026-05-07
PREeMPT
Medical College of Wisconsin
Phase 2
Not yet recruiting
450 enrolled